Immunex Message Board - Msg: 12715965

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LemurHouse who wrote (381)	1/28/2000 5:56:00 PM
From: LemurHouse	Read Replies (1) of 656

FDA panel will recommend approval of Novantrone for advance stage MS. I expect this will contribute an additional 5-10% to IMNX bottom line. Link & article: biz.yahoo.com FDA panel backs Immunex drug Novantrone for MS Friday January 28, 5:35 pm Eastern Time GAITHERSBURG, Md., Jan 28 (Reuters) - A federal advisory panel Friday backed Immunex Corp.'s (NasdaqNM:IMNX - news) cancer drug Novantrone as a treatment for a certain type of multiple sclerosis. A Food and Drug Administration panel voted that Novantrone was safe and effective for treating advanced stages of MS, a disabling neurological disease that can lead to paralysis, blindness and death. The committee's opinion is important because the FDA usually follows its panels' advice. Novantrone already holds FDA approval for treating leukemia and prostate cancer. In clinical trials, Novantrone was given by injection once every three months. The drug likely works by reducing the immune system's attack on the protective sheath that insulates the nerve fibers of the brain and spinal cord, Immunex said. Seattle-based Immunex makes the arthritis treatment Enbrel and other drugs. American Home Products Corp. (NYSE:AHP - news) owns a majority stake in Immunex.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next